Femke Marie Seesing1, Gea Drost2, Johannes Groenewoud2, Gert Jan van der Wilt2, Baziel G M van Engelen2. 1. From the Department of Neurology (F.M.S., G.D., B.G.M.v.E.) and Department for Health Evidence (J.G., G.J.v.d.W.), Radboud University Medical Centre, Nijmegen; and Departments of Neurology and Neurosurgery (G.D.), University Medical Centre Groningen, University of Groningen, the Netherlands. Femke.Seesing@Radboudumc.nl. 2. From the Department of Neurology (F.M.S., G.D., B.G.M.v.E.) and Department for Health Evidence (J.G., G.J.v.d.W.), Radboud University Medical Centre, Nijmegen; and Departments of Neurology and Neurosurgery (G.D.), University Medical Centre Groningen, University of Groningen, the Netherlands.
Abstract
OBJECTIVE: To systematically study the effects of shared medical appointments (SMAs) compared with individual appointments for patients with a chronic neuromuscular disorder and their partners. METHODS: In this randomized controlled trial with a follow-up of 6 months, we included patients with a chronic neuromuscular disorder and their partners. Participants were randomly allocated to an SMA or an individual outpatient appointment. The primary outcome measure was patients' health-related quality of life (QOL) (36-Item Short Form Health Survey). Secondary outcome measures included self-efficacy, social support, patient and partner satisfaction with the appointment, and time available per patient. RESULTS:Two hundred seventy-two patients and 149 partners were included. Health-related QOL showed greater improvement in patients who had attended an SMA (mean difference 2.8 points, 95% confidence interval 0.0-5.7, p = 0.05). Secondary outcomes showed small improvements in the control group for satisfaction with the appointment (p = 0.01). Neurologists spent less time per patient during the SMAs: mean 16 minutes (range 11-30) vs. 25 minutes (range 20-30) for individual appointments. CONCLUSIONS: This study provides evidence that SMAs can improve aspects of QOL of patients with a chronic neuromuscular disorder. This could result in an alternative to individual appointments and improvements in both effectiveness and efficiency. Further research to optimize SMAs and to identify critical success factors seems warranted. These data extend evidence on SMAs for neurologic patients. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with chronic neuromuscular disorders, SMAs improve QOL as compared with individual medical appointments.
RCT Entities:
OBJECTIVE: To systematically study the effects of shared medical appointments (SMAs) compared with individual appointments for patients with a chronic neuromuscular disorder and their partners. METHODS: In this randomized controlled trial with a follow-up of 6 months, we included patients with a chronic neuromuscular disorder and their partners. Participants were randomly allocated to an SMA or an individual outpatient appointment. The primary outcome measure was patients' health-related quality of life (QOL) (36-Item Short Form Health Survey). Secondary outcome measures included self-efficacy, social support, patient and partner satisfaction with the appointment, and time available per patient. RESULTS: Two hundred seventy-two patients and 149 partners were included. Health-related QOL showed greater improvement in patients who had attended an SMA (mean difference 2.8 points, 95% confidence interval 0.0-5.7, p = 0.05). Secondary outcomes showed small improvements in the control group for satisfaction with the appointment (p = 0.01). Neurologists spent less time per patient during the SMAs: mean 16 minutes (range 11-30) vs. 25 minutes (range 20-30) for individual appointments. CONCLUSIONS: This study provides evidence that SMAs can improve aspects of QOL of patients with a chronic neuromuscular disorder. This could result in an alternative to individual appointments and improvements in both effectiveness and efficiency. Further research to optimize SMAs and to identify critical success factors seems warranted. These data extend evidence on SMAs for neurologicpatients. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with chronic neuromuscular disorders, SMAs improve QOL as compared with individual medical appointments.
Authors: Bas C Stunnenberg; Joost Raaphorst; Hans M Groenewoud; Jeffrey M Statland; Robert C Griggs; Willem Woertman; Dick F Stegeman; Janneke Timmermans; Jaya Trivedi; Emma Matthews; Christiaan G J Saris; Bas J Schouwenberg; Gea Drost; Baziel G M van Engelen; Gert Jan van der Wilt Journal: JAMA Date: 2018-12-11 Impact factor: 56.272
Authors: Annemiek Visser; Hanneke W M van Laarhoven; Paulien H M Govaert; Margrethe S Schlooz; Lisette Jansen; Thijs van Dalen; Judith B Prins Journal: J Cancer Surviv Date: 2015-01-13 Impact factor: 4.442
Authors: Lauren S Prescott; Andrea S Dickens; Sandra L Guerra; Jila M Tanha; Desiree G Phillips; Katherine T Patel; Katie M Umberson; Miguel A Lozano; Kathryn B Lowe; Alaina J Brown; Jolyn S Taylor; Pamela T Soliman; Elizabeth A Garcia; Charles F Levenback; Diane C Bodurka Journal: Gynecol Oncol Date: 2015-11-05 Impact factor: 5.482
Authors: Bas C Stunnenberg; Willem Woertman; Joost Raaphorst; Jeffrey M Statland; Robert C Griggs; Janneke Timmermans; Christiaan G Saris; Bas J Schouwenberg; Hans M Groenewoud; Dick F Stegeman; Baziel G M van Engelen; Gea Drost; Gert Jan van der Wilt Journal: BMC Neurol Date: 2015-03-25 Impact factor: 2.474
Authors: Joan M Griffin; Lynette G Stuart-Mullen; Monika M Schmidt; Pamela J McCabe; Thomas J O'Byrne; Megan E Branda; Christopher J McLeod Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2018-07-27